Sarepta Therapeutics, Inc. Overview
Pro stress-test →Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on discovery and development of RNA-targeted therapeutics, gene therapies, and genetic therapeutic modalities for rare diseases. The company engineers precision genetic medicine to reclaim futures impacted by rare diseases, building the world's largest gene therapy manufacturing capacity. Core products include EXONDYS 51, VYONDYS 53, AMONDYS 45 for Duchenne muscular dystrophy exon-skipping, and ELEVIDYS, an AAV-based gene therapy for ambulatory pediatric DMD patients.
Strategic Profile
Pro stress-test →The company is positioned to become cash flow positive and profitable on a non-GAAP basis in 2026 with a robust cash position of $954 million in cash and investments as of Q4 2025. ELEVIDYS is the first gene therapy launched in Japan for Duchenne muscular dystrophy, representing significant market expansion. PMO exon-skipping therapies continue demonstrating durable clinical value with exceptional safety and extraordinary real-world outcomes supported by physicians and families.
Competitive Landscape
Pro stress-test →Sarepta's strategic focus on RNA-targeted technology platforms positions it uniquely in addressing serious diseases. Primary competitors in rare genetic diseases include BioMarin Pharmaceutical, Ultragenyx Pharmaceutical, Solid Biosciences, and Ionis Pharmaceuticals (RNAi focused). Sarepta maintains differentiation through commercial gene therapy and exon-skipping platforms with established patient bases.
Industry Context
Sarepta Therapeutics, Inc. operates in Biopharmaceutical - Precision Genetic Medicine & Gene Therapy.
Key facts
Headquarters: Cambridge, MA, US · Revenue: $2.20B (FY2025) · Market cap: $1.99B